Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE.
Brown JR, Eichhorst B, Lamanna N, O'Brien SM, Tam CS, Qiu L, Jurczak W, Zhou K, Šimkovič M, Mayer J, Gillespie-Twardy A, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, Osterborg A, Yimer HA, Wang M, Salmi T, Wang L, Li J, Wu K, Cohen A, Shadman M.
Blood. 2024 Dec 26;144(26):2706-2717. doi: 10.1182/blood.2024024667.
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia.
Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, McCloskey J, Smith CC, Schiller G, Bradley T, Tiu RV, Naqvi K, Dail M, Brackman D, Siddani S, Wang J, Chyla B, Lee P, Altman JK.
J Clin Oncol. 2022 Dec 10;40(35):4048-4059. doi: 10.1200/JCO.22.00602. Epub 2022 Jul 18.
Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis.
Daver NG, Iqbal S, Renard C, Chan RJ, Hasegawa K, Hu H, Tse P, Yan J, Zoratti MJ, Xie F, Ramsingh G.
J Hematol Oncol. 2023 Mar 6;16(1):19. doi: 10.1186/s13045-023-01417-5.
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML.
Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, King AC, Daniyan AF, Famulare C, Cuello BM, Horvat TZ, Abdel-Wahab O, Levine RL, Viny AD, Stein EM, Cai SF, Roshal M, Tallman MS, Goldberg AD.
Blood Adv. 2021 Mar 9;5(5):1552-1564. doi: 10.1182/bloodadvances.2020003734.
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.
Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, McKeegan E, Salem AH, Zhu M, Ricker JL, Blum W, DiNardo CD, Kadia T, Dunbar M, Kirby R, Falotico N, Leverson J, Humerickhouse R, Mabry M, Stone R, Kantarjian H, Letai A.
Cancer Discov. 2016 Oct;6(10):1106-1117. doi: 10.1158/2159-8290.CD-16-0313. Epub 2016 Aug 12.
Gasdermin E dictates inflammatory responses by controlling the mode of neutrophil death.
Ma F, Ghimire L, Ren Q, Fan Y, Chen T, Balasubramanian A, Hsu A, Liu F, Yu H, Xie X, Xu R, Luo HR.
Nat Commun. 2024 Jan 9;15(1):386. doi: 10.1038/s41467-023-44669-y.
A reversible epigenetic memory of inflammatory injury controls lineage plasticity and tumor initiation in the mouse pancreas.
Falvo DJ, Grimont A, Zumbo P, Fall WB, Yang JL, Osterhoudt A, Pan G, Rendeiro AF, Meng Y, Wilkinson JE, Dündar F, Elemento O, Yantiss RK, Hissong E, Koche R, Betel D, Chandwani R.
Dev Cell. 2023 Dec 18;58(24):2959-2973.e7. doi: 10.1016/j.devcel.2023.11.008. Epub 2023 Dec 5.
DNA damage response defects in hematologic malignancies: mechanistic insights and therapeutic strategies.
Kwok M, Agathanggelou A, Stankovic T.
Blood. 2024 May 23;143(21):2123-2144. doi: 10.1182/blood.2023019963.
Distinct type I and II interferon responses direct cortical and medullary thymic epithelial cell development.
Mohammed A, Wang W, Arreola M, Solomon BD, Slepicka PF, Hubka KM, Nguyen HD, Zheng Z, Chavez MG, Yeh CY, Kim DK, Ma MR, Martin E, Li L, Pasca AM, Winn VD, Gifford CA, Kedlian VR, Park JE, Khatri P, Hollander GA, Roncarolo MG, Sebastiano V, Teichmann SA, Gentles AJ, Weinacht KG.
Sci Immunol. 2025 May 2;10(107):eado4720. doi: 10.1126/sciimmunol.ado4720. Epub 2025 May 2.
Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial.
Kytölä S, Vänttinen I, Ruokoranta T, Partanen A, Holopainen A, Saad J, Kuusisto MEL, Koskela S, Räty R, Itälä-Remes M, Västrik I, Suvela M, Parsons A, Porkka K, Wennerberg K, Heckman CA, Jalkanen T, Huttunen T, Ettala P, Rimpiläinen J, Siitonen T, Pyörälä M, Kuusanmäki H, Kontro M.
Blood. 2025 Jan 23;145(4):409-421. doi: 10.1182/blood.2024024968.
